Skip to main content
OpenTrials
Completed

NCT Number: NCT00467935

Scotoma Reduction in AMD Patients Treated With Ranibizumab

This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Macular Degeneration Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Carbohydrate Metabolism, Inborn Errors Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Eye Diseases Fibrosis Genetic Diseases, Inborn Glycogen Storage Disease Glycogen Storage Disease Type II Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Neurologic Manifestations Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Retinal Degeneration Retinal Diseases Scotoma Sensation Disorders Signs and Symptoms Vision Disorders

Age range

50 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Retina Research Center

Slingerlands, New York, 12159, United States

About this study

Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BCVA < 20/320
  • Disciform macular degeneration wiht exudation

Exclusion criteria

  • Non-amd CNV

Treatment and study plan

intravitreal injection Lucentis (ranibizumab)

Drug

intravitreal injection Lucentis (ranibizumab)

Primary outcomes

  1. scotoma reduction

    Time frame: 12 months

Secondary outcomes

  1. improved visual function

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Retina Research Foundation

Other

Registry information

Official study title

A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis

Acronym: SALVAGE

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
May 1, 2007
Registry last updated
Jul 29, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.